Zeinab Mohsenipour | Biology and Life Sciences | Women Researcher Award

Dr. Zeinab Mohsenipour | Biology and Life Sciences | Women Researcher Award

Dr. Zeinab Mohsenipour | Biology and Life Sciences | Women Researcher Award | Postdoctoral Researcher | Tehran University of Medical Sciences | Iran

Dr. Zeinab Mohsenipour is a distinguished Iranian microbiologist whose scholarly focus and scientific achievements have advanced the field of Medical Bacteriology, particularly in the areas of antimicrobial resistance, bacterial biofilms, and bacteriophage therapy. She earned her Ph.D. in Medical Bacteriology from Tehran University of Medical Sciences, building on her earlier academic foundation with an M.Sc. in Microbiology and a B.A. in Biology from Shahid Bahonar University of Kerman. Throughout her academic and research journey, Dr. Mohsenipour has demonstrated an unwavering commitment to exploring the molecular and clinical mechanisms underlying infectious diseases. Her professional experience encompasses serving as a Research Assistant in the Bacteriology Laboratory at Tehran University of Medical Sciences and as a Lecturer at the University of Science and Culture, where she has taught undergraduate courses in microbial physiology, medical bacteriology, and microbial diversity. Beyond academia, she has also held an industry leadership role as Sales Manager at NojanTeb Azma Company, gaining practical insight into the intersection of scientific innovation and healthcare product development. Her research interests center on the study of antibiotic-resistant pathogens, biofilm inhibition, natural antimicrobial compounds, and the therapeutic application of predatory bacteria and bacteriophages. Dr. Mohsenipour possesses an extensive range of research skills, including bacterial culture and identification, PCR and molecular cloning, antibiotic susceptibility testing, and animal model experimentation, all of which contribute to her capacity for translational biomedical research. Her scientific productivity is evidenced by her numerous peer-reviewed publications in reputable journals indexed in Scopus, Frontiers, and BMC, addressing urgent microbiological issues such as lung infection models and bacterial-based drug delivery systems. Dr. Mohsenipour has also co-authored scientific books that enrich microbiological education, including An Overview of Monoclonal Antibodies: Production Methods and Applications and The Principle of Microbial Physiology. Her contributions have been recognized through invitations to serve as a reviewer for the European Journal of Clinical and Biomedical Sciences and through memberships in esteemed professional societies such as the American Society for Microbiology (ASM) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Dr. Mohsenipour’s excellence in both teaching and research reflects her passion for nurturing scientific inquiry and innovation. Her continuous involvement in international collaborations, advanced workshops, and cutting-edge bacteriological projects underscores her role as a promising and impactful researcher who is shaping the future of microbial science and global health improvement.

Profile: Scopus | ORCID | Google Scholar

Featured Publications 

  1. Mohsenipour, Z., & Hassanshahian, M. (2015). The inhibitory effect of Thymus vulgaris extracts on the planktonic form and biofilm structures of six human pathogenic bacteria. Avicenna Journal of Phytomedicine, 5(4), 309–318. (Citations: 94)

  2. Mohsenipour, Z., & Hassanshahian, M. (2015). The effects of Allium sativum extracts on biofilm formation and activities of six pathogenic bacteria. Jundishapur Journal of Microbiology, 8(8), e18971. (Citations: 78)

  3. Mohsenipour, Z., & Hassanshahian, M. (2016). Antibacterial activity of Euphorbia hebecarpa alcoholic extracts against six human pathogenic bacteria in planktonic and biofilm forms. Jundishapur Journal of Microbiology, 9(6), e34701. (Citations: 63)

  4. Omidinia, E., Shahbazmohammadi, H., & Mohsenipour, Z. (2019). Partitioning of recombinant Pseudomonas putida POS-F84 proline dehydrogenase in aqueous two-phase systems: Optimization using response surface methodology. Applied Biochemistry and Biotechnology, 189, 498–510. (Citations: 32)

  5. Tajabadi, F. H., Karimian, S. M., Mohsenipour, Z., et al. (2022). Biocontrol treatment: Application of Bdellovibrio bacteriovorus HD100 against burn wound infection caused by Pseudomonas aeruginosa in mice. Burns: Journal of the International Society for Burn Injuries. (Citations: 19)

  6. Mohsenipour, Z., Arazi, P., Skurnik, M., et al. (2024). Predation on bacterial pathogens by predatory bacteria of sewage origin: Three days prey-predator interactions. BMC Microbiology, 24, 516. (Citations: 12)

  7. Mohsenipour, Z., Kianian, F., Jahanbin, B., Abtahi, H. R., Ghazanfari, T., Edalatifard, M., Amanpour, S., Skurnik, M., Arazi, P., & Feizabadi, M. M. (2025). Predatory bacteria can intensify lung injury in a multidrug-resistant Acinetobacter baumannii pneumonia model in rat. Frontiers in Microbiology, 16, 1512119. (Citations: 7)

 

Shouping Xu | Biology and Life Sciences | Best Researcher Award

Assoc. Prof. Dr. Shouping Xu | Biology and Life Sciences | Best Researcher Award

Assoc. Prof. Dr. Shouping Xu | Biology and Life Sciences | Medical Physicist | Cancer Hospital Chinese Academy of Medical Sciences | China

Assoc. Prof. Dr. Shouping Xu is a distinguished medical physicist specializing in radiation oncology, with extensive expertise in advanced radiotherapy techniques and the integration of artificial intelligence in cancer treatment. He holds degrees in nuclear physics and medical physics from leading Chinese institutions and has served in senior leadership roles as Chief Clinical Medical Physicist at the Cancer Hospital, Chinese Academy of Medical Sciences, and previously at the Chinese PLA General Hospital and Yi Zhou Proton Therapy Center. Assoc. Prof. Dr. Shouping Xu  has made significant contributions to the development of innovative dose prediction models, proton therapy planning, and image-guided radiotherapy, with numerous publications in high-impact international journals. His active engagement in global conferences, memberships in professional societies, and certifications from recognized boards reflect his commitment to advancing medical physics. Widely respected for both his clinical leadership and research excellence, Assoc. Prof. Dr. Shouping Xu continues to play a key role in shaping the future of precision radiotherapy and medical imaging technologies.

Professional Profile 

Education  

Assoc. Prof. Dr. Shouping Xu has a strong academic background in physics and medical physics, beginning with a Bachelor of Science degree in Nuclear Physics Technology from Lanzhou University, China. He went on to pursue advanced studies at Tsinghua University, where he earned a Master of Science degree in Medical Physics from the Department of Engineering Physics, followed by a Doctor of Philosophy in Medical Physics from the same department. His education provided a solid foundation in radiation physics, imaging, and advanced treatment technologies, which has been central to his career in radiation oncology and his contributions to clinical innovation and research in medical physics.

Professional Experience

Assoc. Prof. Dr. Shouping Xu has built an extensive professional career in medical physics, holding key clinical and leadership positions in some of China’s most renowned cancer treatment centers. He currently serves as Chief Clinical Medical Physicist at the Proton Center of the Cancer Hospital, Chinese Academy of Medical Sciences, where he oversees clinical operations, quality management, and research in advanced radiotherapy. Previously, he was Chief Medical Physicist and Vice Director at the Yi Zhou Proton Therapy Center, where he played a pivotal role in establishing clinical workflows and implementing cutting-edge proton and photon therapies. Earlier in his career, he served at the Chinese PLA General Hospital as Chief and Senior Medical Physicist, contributing to innovations in IMRT, image-guided radiotherapy, and quality assurance. With responsibilities ranging from managing multidisciplinary teams to developing clinical protocols and engaging in pioneering research, Assoc. Prof. Dr. Shouping Xu has consistently demonstrated leadership, technical expertise, and a strong commitment to advancing radiation oncology practices.

Research Interest

Assoc. Prof. Dr. Shouping Xu’s research interests lie at the intersection of medical physics, radiation oncology, and artificial intelligence, with a focus on advancing precision radiotherapy. His work emphasizes the development of AI-driven algorithms and deep learning models for dose prediction, treatment planning, and image-guided radiotherapy, aiming to improve both the efficiency and accuracy of cancer treatment. He has conducted extensive studies on proton therapy, CyberKnife radiosurgery, and advanced techniques such as VMAT, IMRT, and adaptive radiotherapy, contributing to innovations in treatment optimization and quality assurance. Additionally, his research explores deformable image registration, dose verification, and the clinical application of AI for enhancing radiotherapy workflows. By bridging physics, engineering, and oncology, Assoc. Prof. Dr. Shouping Xu is committed to translating cutting-edge technologies into practical clinical tools that improve outcomes and safety for cancer patients.

Award and Honor

Assoc. Prof. Dr. Shouping Xu has earned recognition for his significant contributions to medical physics and radiation oncology through his active involvement in international conferences, professional societies, and research achievements. He has been an invited speaker and presenter at prestigious forums such as the AAPM Annual Meetings, the IUPESM World Congress on Medical Physics and Biomedical Engineering, and the Asia-Oceania Congress of Medical Physics, where his work on advanced radiotherapy techniques and AI-driven innovations has been highlighted. His leadership roles as Chief Clinical Medical Physicist and his certifications from the Chinese Board of Medical Physicists (CBMP) and the Chinese Board of Radiation Protection (CBRP) further underscore his professional excellence. Through his research, publications, and professional service, Assoc. Prof. Dr. Shouping Xu has gained both national and international recognition, reflecting his status as a highly respected figure in the field of medical physics.

Publications Top Noted

Dosimetric evaluation of intensity modulated proton therapy and photon volumetric modulated arc therapy for bilateral breast cancer
Year: 2025

Virtual-simulation boosted neural network dose calculation engine for intensity-modulated radiation therapy
Year: 2025

Dose rate correction of a diode array for universal wedge field dosimetric verification
Year: 2025

gMCAP: a GPU-based Monte Carlo proton transport program for high-density tissues with precise nuclear reaction models
Year: 2025

An AI dose-influence matrix engine for robust pencil beam scanning protons therapy
Year: 2025

A feasibility study of dose-band prediction in radiation therapy: Predicting a spectrum of plan dose
Year: 2025

A StarGAN and transformer-based hybrid classification-regression model for multi-institution VMAT patient-specific quality assurance
Year: 2025

Dose prediction of CyberKnife Monte Carlo plan for lung cancer patients based on deep learning: robust learning of variable beam configurations
Year: 2024

Dosimetric comparison of ZAP-X, Gamma Knife, and CyberKnife stereotactic radiosurgery for single brain metastasis
Year: 2024

Conclusion

Assoc. Prof. Dr. Shouping Xu is highly suitable for the Best Researcher Award. His combination of clinical leadership, innovative research in AI-driven radiation therapy, and active participation in international scientific forums positions him as a thought leader in medical physics and oncology. With his strong portfolio of publications and pioneering approaches to radiation therapy planning and quality assurance, he demonstrates both scientific excellence and clinical relevance. With further emphasis on international collaborations and translational outcomes, his contributions will continue to shape the future of precision radiotherapy.